In Alzheimer’s disease (AD), for example, CSF biomarkers such as α-amyloid Aβ42, total Tau (Tau), and phosphorylated tau (pTau 181) reflect pathology in the AD brain and are now incorporated into the revised clinical diagnostic criteria for AD [6]. This evidence concerns the gene MAPT and Alzheimer disease.